About Enzon Pharmaceuticals (OTCMKTS:ENZN)
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. The company's marketed drug products include PegIntron for chronic hepatitis C; Sylatron for melanoma; Macugen for neovascular wet age-related macular degeneration; and CIMZIA for the treatment of rheumatoid arthritis and Crohn's disease. Enzon Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Cranford, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E Ratio2.37
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$8.38 million
Price / Sales1.38
Cash Flow$0.1231 per share
Price / Cash2.12
Book Value$0.21 per share
Price / Book1.24
EPS (Most Recent Fiscal Year)N/A
Net Income$5.44 million
Return on Equity49.56%
Return on Assets47.88%
Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions
What is Enzon Pharmaceuticals' stock symbol?
Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."
How often does Enzon Pharmaceuticals pay dividends? What is the dividend yield for Enzon Pharmaceuticals?
Enzon Pharmaceuticals declared a dividend on Tuesday, August 15th. Shareholders of record on Wednesday, August 30th will be given a dividend of $0.15 per share on Thursday, September 28th. The ex-dividend date of this dividend is Friday, September 29th. View Enzon Pharmaceuticals' Dividend History.
How were Enzon Pharmaceuticals' earnings last quarter?
Enzon Pharmaceuticals (OTCMKTS:ENZN) issued its quarterly earnings results on Wednesday, August, 10th. The biotechnology company reported $0.02 earnings per share for the quarter. The biotechnology company had revenue of $2.27 million for the quarter. Enzon Pharmaceuticals had a net margin of 64.98% and a return on equity of 49.56%. View Enzon Pharmaceuticals' Earnings History.
When is Enzon Pharmaceuticals' next earnings date?
Who are some of Enzon Pharmaceuticals' key competitors?
Some companies that are related to Enzon Pharmaceuticals include Regenerx Biopharmaceuticals (RGRX), Akari Therapeutics (AKTX), ContraVir Pharmaceuticals (CTRV), DelMar Pharmaceuticals (DMPI), Valeritas (VLRX), AmpliPhi Biosciences (APHB), Bio-Path (BPTH), EnteroMedics (RSLS), Cellectar Biosciences (CLRB), Cesca Therapeutics (KOOL), Sonoma Pharmaceuticals (SNOA), Prana Biotechnology (PRAN), Cormedix (CRMD), ESSA Pharma (EPIX), TrovaGene (TROV), ValiRx (VAL), Fibrocell (FCSC) and Cyclacel (CYCC).
Who are Enzon Pharmaceuticals' key executives?
Enzon Pharmaceuticals' management team includes the folowing people:
- Mr. Andrew Rackear J.D., CEO & Sec. (Age 64)
- Mr. Richard L. Feinstein CPA, VP of Fin. & CFO (Age 75)
Has Enzon Pharmaceuticals been receiving favorable news coverage?
News articles about ENZN stock have trended somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Enzon Pharmaceuticals earned a news sentiment score of 0.16 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 47.19 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Enzon Pharmaceuticals' major shareholders?
How do I buy shares of Enzon Pharmaceuticals?
Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enzon Pharmaceuticals' stock price today?
One share of ENZN stock can currently be purchased for approximately $0.2610.
How big of a company is Enzon Pharmaceuticals?
Enzon Pharmaceuticals has a market capitalization of $11.54 million and generates $8.38 million in revenue each year. Enzon Pharmaceuticals employs 5 workers across the globe.
How can I contact Enzon Pharmaceuticals?
Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]
MarketBeat Community Rating for Enzon Pharmaceuticals (ENZN)MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Enzon Pharmaceuticals (OTCMKTS:ENZN) Analyst Ratings History
(Data available from 4/22/2016 forward)
Enzon Pharmaceuticals (OTCMKTS:ENZN) Earnings History and Estimates Chart
Enzon Pharmaceuticals (OTCMKTS ENZN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2018|| || || || || || || || |
|8/10/2017||Q2 2017||$0.09||$6.78 million||View||N/A|
|5/11/2017||Q1 2017||$0.01||$1.44 million||View||N/A|
|3/24/2017||Q4 2016||($0.10)||$0.85 million||View||N/A|
|11/10/2016||Q3 2016||$0.02||$1.99 million||View||N/A|
|8/10/2016||Q3 2016||$0.02||$2.27 million||View||N/A|
|5/9/2016||Q1 2016||$0.03||$3.27 million||View||N/A|
|3/21/2016||Q4 2015||$0.28||$3.16 million||View||N/A|
|11/6/2015||Q3 2015||($0.04)||$3.84 million||View||N/A|
|8/7/2015||Q2 2015||$0.09||$5.19 million||View||N/A|
|5/13/2015||Q1 2015||$0.16||$5.26 million||View||N/A|
|3/5/2015||Q4 2014||$0.13||$6.27 million||View||N/A|
|11/6/2014||Q3 2014||$0.17||$8.16 million||View||N/A|
|8/8/2014||Q2 2014||$0.16||$7.77 million||View||N/A|
|5/9/2014||Q1 2014||$0.19||$8.98 million||View||N/A|
|3/14/2014||Q4 2013||$0.12||$7.43 million||View||N/A|
|11/12/2013||Q3 2013||$0.13||$8.83 million||View||N/A|
|8/6/2013||Q2 2013||$0.09||$8.06 million||View||N/A|
|5/10/2013||Q1 2013||$0.05||$10.40 million||$10.18 million||View||N/A|
|3/18/2013||Q4 2012||($0.11)||$10.01 million||$10.65 million||View||N/A|
Enzon Pharmaceuticals (OTCMKTS:ENZN) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Enzon Pharmaceuticals (OTCMKTS ENZN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.06%
Institutional Ownership Percentage: 0.09%
Enzon Pharmaceuticals (OTCMKTS ENZN) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/28/2016||Carl C Icahn||Major Shareholder||Buy||694,023||$0.41||$284,549.43|| |
|9/19/2013||Robert Lebuhn||Director||Sell||55,926||$1.72||$96,192.72|| |
|8/10/2012||Robert Lebuhn||Director||Sell||1,933||$6.58||$12,719.14|| |
Enzon Pharmaceuticals (OTCMKTS ENZN) News Headlines
Enzon Pharmaceuticals (OTCMKTS:ENZN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Enzon Pharmaceuticals (OTCMKTS:ENZN) Income Statement, Balance Sheet and Cash Flow Statement
Enzon Pharmaceuticals (OTCMKTS ENZN) Stock Chart for Sunday, April, 22, 2018